bioAffinity Technologies (BIAF) Retained Earnings (2021 - 2026)

bioAffinity Technologies (BIAF) has reported Retained Earnings for 6 consecutive years, with -$72.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 28.23% year-over-year to -$72.2 million; the TTM figure through Mar 2026 stood at -$72.2 million (down 28.23% YoY), while the FY2025 annual figure was -$68.6 million, down 27.79% from the prior year.
• Retained Earnings fell to -$72.2 million in Q1 2026 per BIAF's latest filing, from -$68.6 million in the prior quarter.
• Across five years, Retained Earnings topped out at $74.3 million in Q3 2025 and bottomed at -$72.2 million in Q1 2026.
• Historically, Retained Earnings has averaged -$8.0 million across 5 years, with a median of -$38.2 million in 2023.
• Annual changes were most pronounced in 2022 — Retained Earnings jumped 267.12% — and 2025, when it plunged 208.81%.
• bioAffinity Technologies' Retained Earnings stood at $47.7 million in 2022, then gained by 3.66% to $49.4 million in 2023, then plunged by 208.6% to -$53.6 million in 2024, then fell by 27.79% to -$68.6 million in 2025, then decreased by 5.32% to -$72.2 million in 2026.
• Business Quant data shows BIAF's Retained Earnings at -$72.2 million in Q1 2026, -$68.6 million in Q4 2025, and $74.3 million in Q3 2025.